Creative Biolabs is dedicated to propelling the advancement of immunotherapy and cell-based therapies. Our CellFace™ cell-antibody conjugate products represent a breakthrough in the development of targeted cancer treatments. These products leverage the power of antibody-conjugated cell (ACC) technology to enhance the efficacy and specificity of cell-based therapies.
The principle of ACC technology involves binding cell surface markers to specific antibodies and then coupling these antibodies with fluorescent dyes or magnetic beads to form complexes. The specific signals from the fluorescent dyes or magnetic beads can be used to detect, separate, and purify specific surface markers on the cell membrane. This technology can be applied to various types of cell analysis, including cell sorting, flow cytometry, fluorescence microscopy, magnetic separation, and cell immunofluorescence detection. In flow cytometry, ACC technology is often used to detect specific immune cell subsets, surface markers, or cytokine expression levels. In drug development, ACC technology is also used to screen and evaluate drug molecules that may interact with cell surface markers and matrices.
Creative Biolabs has innovated a one-step chemoenzymatic platform, known as CellFace™, which enables the transfer of biomolecules, including IgG antibodies (approximately 150 KD in molecular weight), to the glycocalyx layer on the surfaces of viable cells, all without the need for genetic modification. This allows any antibody to be coupled with the stimulatory surface receptors of immune cells, enhancing their tumor targeting effects on top of their existing potent and readily available therapeutic payloads. Using the CellFace™ method, we have constructed CellFace™ T cell-antibody conjugates, which are built from T cell lines modified with therapeutic antibodies. It is anticipated that the modified T cell conjugates will demonstrate targeted tumor recognition capabilities and serve as a valuable research instrument for exploring therapeutic applications.
Creative Biolabs' CellFace™ cell-antibody conjugate products represent a major advancement in the field of immunotherapy and cell-based therapies. By harnessing the power of ACC technology, these products offer a promising approach for the treatment of cancer and other diseases. Our dedication lies in relentless innovation and the creation of new products aimed at enhancing the well-being of patients globally. For comprehensive information, we invite customers to contact our company for additional queries.
All services are only provided for research purposes and Not for clinical use.
